Amber Bio, a San Francisco based developer of gene editing platforms to reach undruggable diseases, announced $26M in funding from a16z, Playground Global, Eli Lilly, Hummingbird Ventures and Pillar VC.
The big idea:
- Amber Bio is developing an innovative RNA editing platform that aims to correct genetic mutations in a safe, reversible way
- If successful, the technology would be able to edit thousands of of different, diverse mutations across patients with one single product
- Current gene editing technology treats one single genetic mutation at a time, which is not scaleable for patients
